CAS 2326521-71-3: MRTX-849

Adagrasib

MRTX849 is a small molecule inhibitor, which is derived through rational drug design targeting specific oncogenic mutations. It acts as a covalent inhibitor that selectively targets the KRAS G12C mutation, a prevalent alteration in various cancers such as non-small cell lung cancer and colorectal cancer. The mode of action involves binding to the mutated KRAS G12C protein, locking it in an inactive GDP-bound state, thereby inhibiting downstream signaling pathways crucial for tumor cell proliferation and survival. The primary use of MRTX849 is in the treatment of cancers harboring the KRAS G12C mutation. By selectively targeting this mutation, it offers a tailored therapeutic approach that potentially enhances efficacy while minimizing off-target effects compared to conventional chemotherapy. Ongoing clinical trials are evaluating its efficacy and safety profile, with promising results that underscore its potential to become a critical component in precision oncology for patients with KRAS-driven tumors.

2-((S)-4-(7-(8-Chloronaphthalen-1-Yl)-2-(((S)-1-Methylpyrrolidin-2-Yl)Methoxy)-5,6,7,8-Tetrahydropyrido[3,4-D]Pyrimidin-4-Yl)-1-(2-Fluoroacryloyl)Piperazin-2-Yl)Acetonitrile

View and buy Adagrasib (MRTX849) from TargetMol.MRTX849 is a potent, selective and covalent KRASG12C inhibitor with potential antineoplastic activity. Cited in 2 publications.